A UK-based academic nephrologist specializing in kidney disease and IgA nephropathy management shares perspectives on IgAN patient classification, epidemiology, the treatment journey, use of targeted therapies (budesonide/Kinpeygo and sparsentan), market access and reimbursement via NICE in the UK, and areas of unmet need. In addition, the KOL shares views on emerging therapies.

This interview was conducted on March 26, 2026.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.